ArticleTherapeutic advances in medical oncology2025
The prognostic role of the neutrophil-to-lymphocyte ratio in metastatic urothelial carcinoma.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation has been linked to cancer progression and survival outcomes. The neutrophil-to-lymphocyte ratio (NLR) is a readily available biomarker that may reflect this process in metastatic urothelial carcinoma (mUC). Objectives: To evaluate the prognostic impact of baseline NLR on overall survival in mUC patients receiving chemotherapy or immunotherapy. Design: A multicenter retrospective cohort study. Methods: We retrospectively analyzed 196 patients with advanced, unresectable urothelial carcinoma treated at four centers (Ankara University School of Medicine, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara Bilkent City Hospital, and Gazi University School of Medicine) between 2005 and 2023. These patients were stratified into high and low NLR groups using a cutoff of 4.2. Survival outcomes were assessed using Kaplan-Meier curves, and the prognostic significance of NLR was evaluated using univariate (log-rank test) and multivariate (Cox proportional hazards model) analyses. Results: The median overall survival (OS) for the entire cohort was 27 months (95% CI: 19.1-34.9). Patients with low NLR had significantly longer OS than those with high NLR (56.6 vs 14.6 months; Conclusion: Elevated NLR is an independent prognostic marker in mUC, underscoring the role of systemic inflammation in cancer progression. These findings highlight the potential of NLR as a readily available biomarker for risk stratification in mUC, irrespective of treatment modality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.